- Home
- GAME vs EVAX Comparison
GAME vs EVAX Comparison
Compare GAME & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | EVAX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 31.9M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GAME | EVAX |
|---|---|---|
| Price | $0.25 | $3.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 846.7K | 31.7K |
| Earning Date | 05-14-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $96,198,101.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 85.00 | N/A |
| 52 Week Low | $0.26 | $1.20 |
| 52 Week High | $2.87 | $12.15 |
Technical Indicators
Market Signals| Indicator | GAME | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 33.78 | 46.95 |
| Support Level | N/A | $2.45 |
| Resistance Level | $0.32 | $3.62 |
| Average True Range (ATR) | 0.02 | 0.41 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 3.63 | 30.00 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.